ixabepilone
Sign in to saveAlso known as BMS-247550-01, Ixempra, Aza-epothilone B, Azaepothilone B, Ixempra Kit, BMS-247550
Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is a pharmaceutical drug developed by Bristol-Myers Squibb as a chemotherapeutic medication for cancer.
Research
484 papers- Ixabepilone.2012
- Ixabepilone.Clinical journal of oncology nursing · 2010
- Ixabepilone-Induced Delirium.American journal of therapeutics · 2024
- Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer.Frontiers in oncology · 2021
- A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.Gynecologic oncology · 2018
via PubMed
~2 min read
Encyclopedic overview
6 sectionsContents
- History
- Pharmacology
- Approval
- Clinical uses
- References
- External links
Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is a pharmaceutical drug developed by Bristol-Myers Squibb as a chemotherapeutic medication for cancer.
==History== Ixabepilone is a semi-synthetic analog of epothilone B, a natural chemical compound produced by Sorangium cellulosum. The structural difference between Epothilone B and Ixabepilone consists of only a single atom oxygen-to-nitrogen subsitution that converts the ester into an amide. Epothilone B itself could not be developed as a pharmaceutical drug because of poor metabolic stability and pharmacokinetics. Ixabepilone was designed through medicinal chemistry to improve upon these properties.
Excerpted from Wikipedia’s “ixabepilone” article, available under the CC BY-SA 4.0 licence.
Available in 13 languages
- Español
- العربية
- Bahasa Indonesia
- Odia
- Polski
- Romanian
- Serbian
- Serbian (Latin)
- Telugu
- Tiếng Việt
- Ukrainian
- فارسی
via Wikidata sitelinks · CC0